Provided by Tiger Trade Technology Pte. Ltd.

Supernus Pharmaceuticals

42.92
+1.543.72%
Post-market: 42.920.00000.00%19:30 EDT
Volume:559.77K
Turnover:23.98M
Market Cap:2.49B
PE:-22.42
High:43.40
Open:41.66
Low:41.46
Close:41.38
52wk High:59.68
52wk Low:40.51
Shares:58.04M
Float Shares:51.67M
Volume Ratio:0.78
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9145
EPS(LYR):-0.6829
ROE:-10.49%
ROA:0.39%
PB:2.42
PE(LYR):-62.85

Loading ...

Indivior Sets USD 8.13 Special Dividend Tied to Supernus Merger Closing

Reuters
·
Yesterday

Supernus Pharmaceuticals to Participate in September Investor Conferences

GlobeNewswire
·
Sep 03

Supernus Pharmaceuticals (SUPN) On Chloe Kim ADHD Push And Whether Undervalued Looks Priced In

Simply Wall St.
·
Sep 02

Inventiva Names Chris Benecchi Chief Operating Officer

Reuters
·
Sep 01

Supernus Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

U.S. Stocks on the MOVE -Visa, Bowhead Specialty, Micron

Reuters
·
Aug 03

UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate

Benzinga Earnings
·
Aug 03

Supernus, Indivior Merge to Strengthen Neuroscience Drug Portfolio

Reuters
·
Aug 03

Supernus Pharmaceuticals Swings to Q2 Net Loss, Revenue Rises; Fiscal 2026 Revenue Outlook Raised

MT Newswires Live
·
Aug 03

Indivior Pharmaceuticals, Supernus Pharmaceuticals to Combine in All-Stock Merger

MT Newswires Live
·
Aug 03

Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q2 Net Loss $1.01 a Share, vs. FactSet Est of $0.04 EPS

MT Newswires Live
·
Aug 03

Supernus Pharmaceuticals Q2 EPS USD -1.01

Reuters
·
Aug 03

Supernus Q2 FY26 Net Loss Widens to $58.4 Million; Revenue Rises 32% to $219.1 Million

Reuters
·
Aug 03

Supernus Pharmaceuticals Shares Rise 5.3% Premarket After Co to Merge with Indivior Pharmaceuticals

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Q2 Product Sales USD 165.7 Million

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Outlook FY Revenue USD 860-890 Million

THOMSON REUTERS
·
Aug 03

Supernus Announces Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 03

Supernus, Indivior Agree All-Stock Merger, Combined Firm to Trade as Supernus on NASDAQ

Reuters
·
Aug 03

Supernus Pharmaceuticals - Stockholders Will GET 1.5401 Common Shares of Indivior Pharmaceuticals for Each Share of Supernus Pharmaceuticals They Own

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc: Indivior Pharmaceuticals Stockholders Will Own Approximately 56.5% of Combined Company

THOMSON REUTERS
·
Aug 03